Figure 3: Inhibiting LDLR Expression With PCSK9 or LDLR Function With a Blocking Antibody Does Not Affect Lp(a) Uptake by Human Primary Hepatocytes

Cells were treated with recombinant PCSK9 (± alirocumab) or an anti-LDLR blocking antibody (Ab). An isotype control antibody was used as control (Ctrl). Fluorescent LDL (A) and fluorescent Lp(a) (B) cellular uptake was measured. *p < 0.001 vs. control (black bars). **p < 0.001 vs. PCSK9 treatment (white bars). ***p < 0.001 vs. anti-LDLR blocking antibody (light gray bars), using 1-way analysis of variance analysis on rank-transformed values with post-hoc Newman-Keuls test. Histograms represent the mean ± SEM of 7 independent experiments from 2 hepatocyte donors. Abbreviations as in Figures 1 and 2.